Dallas, Texas – December 10, 2019 — – North American Cannabis Holdings, Inc. (OTC Pink: USMJ) (“USMJ”) today introduced Nano Enhanced Broad Spectrum CBD Oil now for sale
on the company’s eCommerce site www.USMJ.com. The eCommerce site was launched earlier this year and after refining and adjusting the site through an initial pilot phase, the company is now adding new products regularly to become a major brand recognized online retail site for CBD, Hemp and Cannabis Essentials. The company plans to regularly feature new products throughout December.
Today the company is introducing introduced Nano Enhanced Broad Spectrum CBD Oil:
SpaRoom Broad Spectrum CBD Oil contains 250 MG of CBD that is derived from organically grown industrial hemp, which is processed at a Colorado Department of Public Health and Environment licensed facility. This product contains a wide range of synergistic cannabinoids to promote the most complete absorption within the body. Nano-technology reduces molecular size for the highest bioavailability and fullest absorption of CBD oil. This product is THC-free and non-GMO. This product is manufactured in a GMP compliant facility and is third-party HPLC tested for potency.
- Water solubility allows this CBD oil to be diffused in a diffuser or blended with any desired substances.
- Place 1 mL dropper into any desired substance. 1 mL dropper is approximately 8 MG of CBD.
- For Aromatherapy Uses: Add 1 mL dropper to aromatherapy diffuser.
- For Topical Application: Apply directly to skin for benefits including: moisturizing, smoothing, soothing/calming and tension relief
USMJ launched its eCommerce business earlier this year and the site continues to evolve and grow as the company invests to make USMJ a major brand name in the CBD, Hemp and Cannabis marketplace.
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
CEO North American Cannabis Holdings, Inc.